ZYBERNO
Stock Report
Updated Aug 30, 2026

Dyne Therapeutics, Inc. (DYN)

Healthcare • NASDAQ

$25.07

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Dyne Therapeutics, Inc. (DYN) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-64.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.29x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-174.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Dyne Therapeutics, Inc. (DYN) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, DYN generated -$443.40M in Owner Earnings. Capital was deployed as follows: $1.16M invested in capital expenditures. Reinvestment rate: 0.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:25.07
Market Cap:$4.15B

Valuation Multiples (2)

P/B Ratio:5.92x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.68B

Price Action & Momentum (3)

Momentum Percentile:94 / 100
% of 52-Week High:91.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-50.3%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$13.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-19.3%
Latest Earnings Filed:2026-07-29
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:12.02x
Quick Ratio:12.02x
Cash Ratio:8.66x

Leverage Analysis (3)

Debt To Equity Ttm:0.29x
Debt-to-Equity Ratio:0.29x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-161.22x
Times Interest Earned:-161.22

Capital Structure (4)

Working Capital:859,860,000.00
Cash And Cash Equivalents:676,114,000.00
Long Term Debt:$199.33M
Net Debt:-$471.42M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$536.96M

Bottom Line Performance (3)

-$519.41M
Income Before Tax:$0.00
Ebitda Ttm:-534,761,000.00

Operating Expenses (5)

Operating Expenses:536,958,000.00
R And D Expense:445,708,000.00
Sga Expense:91,250,000.00
Income Tax Expense:$0.00
Interest Expense:2,904,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$994.01M
Current Assets:$937.89M
Ppe Net:24,559,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:291,862,000.00
Current Liabilities:78,029,000.00
Long Term Debt:$199.33M
Short Term Debt:$5.37M

Equity & Capital (3)

Equity:$702.15M
Retained Earnings:-$1.70B
Common Stock:400,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:12,153,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:14,976,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$442.24M-$443.40M

Investment Activities (2)

Investing Cash Flow:-$2.39M
Capital Expenditures Ttm:1,160,000.00

Financing Activities (3)

Financing Cash Flow:$7.06M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$9.94M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,197,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.26
-$3.26
Earnings Per Share Ttm:-$3.14

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.43

Book Value & Capital (2)

Book Value Per Share:$4.24
Cash Per Share:4.08

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$443.40M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):40.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:DYN
Company Name:Dyne Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:165.67M
Shares Outstanding Basic:165.67M
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 21:11:46 UTC
Data Timestamp:2026-08-30T21:11:46.469554
Scroll to Top